You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明生物(02269.HK)擬配售1.18億股新股份 總籌132.16億港元
格隆匯 02-03 07:43

格隆匯 2 月 3日丨藥明生物(02269.HK)發佈公吿,2021年2月2日,公司與摩根士丹利(作為配售代理)訂立一級配售協議,據此,配售代理同意向目前預期不少於六名獨立第三方投資者按悉數包銷基準及每股112.00港元的價格配售(或如未能配售,則由配售代理以主事人身份自行購買)1.18億股一級配售股份。一級配售須待聯交所上市委員會批准一級配售股份上市及買賣後,方可作實。一級配售股份將根據一般授權發行。

假設於本公吿日期至一級配售完成公司已發行股本不會發生任何變動,一級配售股份相當於公司現有已發行股本約2.88%;及公司經發行及配發一級配售股份擴大的已發行股本約2.80%。

假設一級配售股份獲悉數配售,預期一級配售的所得款項總額將約為132.16億港元、所得款項淨額將約為131.2124億港元及每股一級配售股份的淨價將約為111.20港元。其中,公司擬將一級配售所得款項淨額約40%將用於併購原液╱製劑(DS/ DP)生產的額外設施以配合迅速增長的研發管線;約40%將用於為多個技術平台(包括微生物及哺乳動物細胞平台)建設更多大型生產設施;約10%將用於mRNA(信使核糖核酸)相關技術投資以進一步賦能其全球客户;及約10%將用作集團的一般營運用途。董事(包括獨立非執行董事)認為一級配售是公司籌集額外資本以為其未來擴張提供資金的良機且與其當前的業務發展步調一致。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account